😒🚬
The stock price of vTv Therapeutics Inc. (Nasdaq: VTVT) – a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis – increased by over 10% pre-market. Investors appear to be responding to the company announcing that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes. TTP399 is a novel / oral / investigational once-daily glucokinase activator.
😒🚬
The stock price of vTv Therapeutics Inc. (Nasdaq: VTVT) – a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis – increased by over 10% pre-market. Investors appear to be responding to the company announcing that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes. TTP399 is a novel / oral / investigational once-daily glucokinase activator.